Evidence map›Paper›PMID 39080260›Full record

ArticleCell death & disease2024

HMGA1 promotes the progression of esophageal squamous cell carcinoma by elevating TKT-mediated upregulation of pentose phosphate pathway.

Meng-Jie Liu, Yuan Zhao, Qiu-Tong Li, Xin-Yuan Lei, Kai-Yue He, Jin-Rong Guo, Jing-Yu Yang, Zhen-Hua Yan, Dan-Hui Wu, Lei Zhang and 2 more

Registry-linked trialAbstract read
In one paragraph

Article in Cell death & disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07450833 (Assessing the Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine), which is not on this map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07450833 phase1completednot on this map

Assessing the Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers - An Open Label, Phase I Study

TypeinterventionalSponsorBenfovir AGRan2022 to 2022Enrolled48ConditionsHealthy VolunteersArmsBenfo-oxythiamine
3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. The role of HMGA1 in genome stability: Implications in human cancer.Cellular and molecular life sciences : CMLS · 2026
    Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Meng-Jie Liu *School of Life Sciences, Henan University, Kaifeng, Henan Province, China.
Yuan Zhao *School of Life Sciences, Henan University, Kaifeng, Henan Province, China.
Qiu-Tong Li *School of Life Sciences, Henan University, Kaifeng, Henan Province, China.
Xin-Yuan LeiSchool of Life Sciences, Henan University, Kaifeng, Henan Province, China.
Kai-Yue HeSchool of Life Sciences, Henan University, Kaifeng, Henan Province, China.
Jin-Rong GuoSchool of Life Sciences, Henan University, Kaifeng, Henan Province, China.
Jing-Yu YangSchool of Life Sciences, Henan University, Kaifeng, Henan Province, China.
Zhen-Hua YanSchool of Life Sciences, Henan University, Kaifeng, Henan Province, China.
Dan-Hui WuSchool of Life Sciences, Henan University, Kaifeng, Henan Province, China.
Lei ZhangSchool of Life Sciences, Henan University, Kaifeng, Henan Province, China.
Yong-Ping JianSchool of Life Sciences, Henan University, Kaifeng, Henan Province, China. yongpingjian123@163.com.ORCID 0000-0002-0676-2247
Zhi-Xiang XuSchool of Life Sciences, Henan University, Kaifeng, Henan Province, China. zhixiangxu08@gmail.com.ORCID 0000-0002-2385-3044

Funding

China Postdoctoral Science Foundation 2022M721014National Natural Science Foundation of China (National Science Foundation of China) 82020108024
6 · The paper itself

Abstract

Esophageal squamous cell carcinoma (ESCC) possesses a poor prognosis and treatment outcome. Dysregulated metabolism contributes to unrestricted growth of multiple cancers. However, abnormal metabolism, such as highly activated pentose phosphate pathway (PPP) in the progression of ESCC remains largely unknown. Herein, we report that high-mobility group AT-hook 1 (HMGA1), a structural transcriptional factor involved in chromatin remodeling, promoted the development of ESCC by upregulating the PPP. We found that HMGA1 was highly expressed in ESCC. Elevated HMGA1 promoted the malignant phenotype of ESCC cells. Conditional knockout of HMGA1 markedly reduced 4-nitroquinoline-1-oxide (4NQO)-induced esophageal tumorigenesis in mice. Through the metabolomic analysis and the validation assay, we found that HMGA1 upregulated the non-oxidative PPP. With the transcriptome sequencing, we identified that HMGA1 upregulated the expression of transketolase (TKT), which catalyzes the reversible reaction in non-oxidative PPP to exchange metabolites with glycolytic pathway. HMGA1 knockdown suppressed the PPP by downregulating TKT, resulting in the reduction of nucleotides in ESCC cells. Overexpression of HMGA1 upregulated PPP and promoted the survival of ESCC cells by activating TKT. We further characterized that HMGA1 promoted the transcription of TKT by interacting with and enhancing the binding of transcription factor SP1 to the promoter of TKT. Therapeutics targeting TKT with an inhibitor, oxythiamine, reduced HMGA1-induced ESCC cell proliferation and tumor growth. Together, in this study, we identified a new role of HMGA1 in ESCCs by upregulating TKT-mediated activation of PPP. Our results provided a new insight into the role of HMGA1/TKT/PPP in ESCC tumorigenesis and targeted therapy.

Indexed as

Disease ProgressionEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaHMGA1a ProteinPentose Phosphate PathwayTransketolaseUp-RegulationAnimalsCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticHumansMiceMice, NudeSp1 Transcription FactorTransient Receptor Potential ChannelsHMGA1a ProteinHMGA1 protein, humanMcoln1 protein, mouseSp1 Transcription FactorTransient Receptor Potential ChannelsTransketolase

Identifiers

PMID39080260
PMCPMC11289123

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.